Acetylcholinesterase inhibitors are associated with reduced fracture risk among older Veterans with dementia.

Clicks: 303
ID: 65005
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #2 of 122 articles by views in journal of bone and mineral research : the official journal of the american society for bone and mineral research

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 122 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Acetylcholinesterase inhibitors (AChEIs) have been noted to increase bone density and quality in mice. Human studies are limited but suggest an association with improved bone healing after hip fracture. We examined the relationship between AChEIs use and fracture risk in a national cohort of 360,015 male Veterans aged 65-99 years with dementia but without prior fracture using Veterans Affairs (VA) hospital, Medicare, and Pharmacy records from 2000-2010. Diagnosis of dementia, any clinical fracture (excluding facial and digital), comorbidities and medications were identified using ICD-9 and drug class codes. Cox proportional hazard models considering AChEIs use as a time-varying covariate and adjusting for fall and fracture risk factors compared the time-to-fracture in AChEIs users vs. non-AChEIs users. Potential confounders included demographics (age, race, BMI), comorbidities associated with fracture or falls (diabetes, lung disease, stroke, Parkinson's, seizures, etc.) and medications associated with fracture or falls (bisphosphonates, glucocorticoids, androgen deprivation therapy (ADT), proton pump inhibitors (PPIs), selective serotonin receptors inhibitors (SSRIs), etc.). Competing mortality risk was considered using the methods of Fine and Gray. To account for persistent effects on bone density or quality that might confer protection after stopping the medication, we completed a secondary analysis using the Medication Possession Ratio (MPR) as a continuous variable in logistic regression models, and also compared MPR increments of 10% to minimal/no use (MPR 0 to <0.10). Among older Veterans with diagnosis of dementia, 20.1% suffered a fracture over an average of 4.6 years of follow-up. Overall, 42.3% of the cohort were prescribed AChEIs during the study period. The hazard of any fracture among AChEIs users compared to those on other/no dementia medications was significantly lower in fully adjusted models (HR 0.81; 95% CI, 0.75-0.88). After considering competing mortality risk, fracture risk remained 18% lower in Veterans using AChEIs (HR 0.82; 95% CI, 0.76-0.89). This article is protected by copyright. All rights reserved.
Reference Key
ogunwale2019acetylcholinesterasejournal Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ogunwale, Abayomi N;Colon-Emeric, Cathleen S;Sloane, Richard;Adler, Robert A;Lyles, Kenneth W;Lee, Richard H;
Journal journal of bone and mineral research : the official journal of the american society for bone and mineral research
Year 2019
DOI
10.1002/jbmr.3916
URL
Keywords
snp array, williams-beuren syndrome congenital cardiovascular abnormalities, expanded noninvasive prenatal testing, prenatal diagnosis

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.